These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6223646)

  • 1. Desogestrel, a new progestational compound, and the liver.
    Weijers MJ
    Arzneimittelforschung; 1983; 33(5):774-6. PubMed ID: 6223646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol.
    Benagiano G
    Int J Fertil; 1989 Sep; 34 Suppl():31-9. PubMed ID: 2576255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre study with a new biphasic oral contraceptive containing ethinylestradiol and desogestrel. Report on efficacy, cycle control and adverse experiences with special emphasis on blood pressure and weight.
    Dieben TO; van Beek A; Coelingh Bennink HJ
    Arzneimittelforschung; 1991 Sep; 41(9):996-8. PubMed ID: 1839126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new progestagen for oral contraception.
    De Jager E
    Contracept Deliv Syst; 1982 Jan; 3(1):11-5. PubMed ID: 12264122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
    Jung-Hoffmann C; Fitzner M; Kuhl H
    Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The combined effect of an ethinylestradiol/desogestrel contraceptive combination on blood lipids and parameters of liver function and coagulation].
    Massafra C; Capitani S; Bernabei A; Scillone L
    Rev Fr Gynecol Obstet; 1988 Apr; 83(4):251-5. PubMed ID: 2969134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative metabolic effects of oral contraceptive preparations containing different progestagens. Effects of desogestrel + ethinylestradiol on the haemostatic balance.
    Rákóczi I; Gerö G; Demeter J; Gáti I
    Arzneimittelforschung; 1985; 35(3):630-3. PubMed ID: 3158320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.
    Akerlund M
    Acta Obstet Gynecol Scand Suppl; 1997; 164():63-5. PubMed ID: 9225641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
    Coenen CM; Thomas CM; Borm GF; Rolland R
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():92-7. PubMed ID: 8574256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hemostatic balance during treatment with the newest contraceptives].
    Petersen KR; Skouby SO; Sidelmann J; Jespersen J
    Ugeskr Laeger; 1994 Jan; 156(2):187-90. PubMed ID: 8296409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive.
    Bilotta P; Favilli S
    Arzneimittelforschung; 1988 Jul; 38(7):932-4. PubMed ID: 2974702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrinological studies with desogestrel.
    van der Vies J; de Visser J
    Arzneimittelforschung; 1983; 33(2):231-6. PubMed ID: 6221730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of oral contraceptive combinations containing levonorgestrel or desogestrel on serum proteins and androgen binding.
    Bergink EW; Holma P; Pyörälä T
    Scand J Clin Lab Invest; 1981 Nov; 41(7):663-8. PubMed ID: 6461916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of hormonal contraceptives containing 0.05 mg ethinyl estradiol and 0.125 mg desogestrel in normophasic regimen (Oviol)].
    Weijers MJ
    Fortschr Med; 1982 Apr; 100(16):764-7. PubMed ID: 6211403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an oral contraceptive containing a new progestogen, desogestrel, and 30 micrograms ethinylestradiol. Report on clinical studies from Scandinavia.
    Acta Obstet Gynecol Scand Suppl; 1982; 111():1-60. PubMed ID: 6216716
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hypophyseal reaction state during oral contraceptiva (author's transl)].
    Gitsch E; Schneider WH; Schmid R; Spona J
    Wien Klin Wochenschr; 1981 Oct; 93(19):599-601. PubMed ID: 6798764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of oral contraceptive containing a new progestin (ORG 2969) on plasma renin activity, growth hormone and immunoreactive insulin.
    Liukko P; Erkkola R; Lammintausta R
    Ann Chir Gynaecol; 1979; 68(5-6):155-9. PubMed ID: 161858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cycle control and side effects of a new combiphasic oral contraceptive regimen.
    Dieben TO; op ten Berg MT; Coelingh Bennink HJ
    Arzneimittelforschung; 1994 Jul; 44(7):877-9. PubMed ID: 7945527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate.
    Charoenvisal C; Thaipisuttikul Y; Pinjaroen S; Krisanapan O; Benjawang W; Koster A; Doesburg W
    Int J Fertil Menopausal Stud; 1996; 41(4):423-9. PubMed ID: 8894800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.